Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;5(4):410-423.
doi: 10.21037/tcr.2016.06.19.

The emerging field of radiomics in esophageal cancer: current evidence and future potential

Peter S N van Rossum  1   2 , Cai Xu  1   3 , David V Fried  4 , Lucas Goense  2 , Laurence E Court  5 , Steven H Lin  1
Affiliations

The emerging field of radiomics in esophageal cancer: current evidence and future potential

Peter S N van Rossum et al. Transl Cancer Res. 2016 Aug.

Abstract

'Radiomics' is the name given to the emerging field of extracting additional information from standard medical images using advanced feature analysis. This innovative form of quantitative image analysis appears to have future potential for clinical practice in patients with esophageal cancer by providing an additional layer of information to the standard imaging assessment. There is a growing body of evidence suggesting that radiomics may provide incremental value for staging, predicting treatment response, and predicting survival in esophageal cancer, for which the current work-up has substantial limitations. This review outlines the available evidence and future potential for the application of radiomics in the management of patients with esophageal cancer. In addition, an overview of the current evidence on the importance of reproducibility of image features and the substantial influence of varying smoothing scales, quantization levels, and segmentation methods is provided.

Keywords: Radiomics; computed tomography; esophageal cancer; positron emission tomography; texture analysis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Steven H. Lin has research grant support from Elekta, STCube Pharmaceuticals, Roche/ Genentech, and Peregrine Pharmaceuticals, and has received honorarium from AstraZeneca and US Oncology. The other authors have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet 2013; 381:400–12. - PubMed
    1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241–52. - PubMed
    1. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992–1000; discussion 1000–1. - PubMed
    1. Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010;116:3763–73. - PubMed
    1. Bhatt A, Abe S, Kumaravel A, et al. Indications and Techniques for Endoscopic Submucosal Dissection. Am J Gastroenterol 2015;110:784–91. - PubMed